Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Halozyme Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
No intraday reading yet this session.
671 institutional managers report a position in Halozyme Therapeutics, Inc. worth $9.7B between them, filed on form 13F for the quarter ending 2026-06-30. 58 of them hold 80% of it, the largest being BlackRock, Inc. at 10.71%.
646 more managers in the register
58 managers hold 80% of the $9.7B institutional base. The other 613 hold the rest.
Positions as filed with the SEC for the quarter ended Jun 30. A 13F is due 45 days after the quarter closes, so this register is 78 days old and does not move with the price above it.
via Boston Partners, Arrowstreet Capital, Limited Partnership, Fuller & Thaler Asset Management, Inc. +11 more · 2.23% of HALO, 2.08% of CHE
via Arrowstreet Capital, Limited Partnership, Boston Partners, GW&K Investment Management, LLC +13 more · 1.38% of HALO, 1.43% of GMED
via Boston Partners, William Blair Investment Management, LLC, Arrowstreet Capital, Limited Partnership +8 more · 2.23% of HALO, 1.88% of CHDN
via Boston Partners, Fuller & Thaler Asset Management, Inc., Norges Bank +9 more · 2.23% of HALO, 3.72% of ALSN
via Boston Partners, Arrowstreet Capital, Limited Partnership, First Trust Advisors LP +9 more · 2.23% of HALO, 1.97% of BYD
via Arrowstreet Capital, Limited Partnership, Fuller & Thaler Asset Management, Inc., LSV Asset Management +10 more · 1.38% of HALO, 1.68% of EXEL
Managers holding a meaningful stake in HALO also hold this much of the other company’s institutional base. Managers who hold most of the companies we cover are excluded, because their overlap says nothing about this one in particular. This is how the two are held, not evidence that one moves the other.
HALO (Halozyme Therapeutics, Inc.) has 14 disclosed suppliers and 20 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: SKYE +1.90%, in the health bundle.